Loading…

Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service

Objective: To identify the most common diseases and age of corticosteroid use in women over 50, dosage in last year, duration of oral corticosteroid use, prescription for fracture prevention (drug used), and referrals for bone densitometry. Methods: General practice records from 41 practices in Shro...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2003-04, Vol.62 (4), p.350-352
Main Authors: Chantler, I W, Davie, M W J, Evans, S F, Rees, J S
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To identify the most common diseases and age of corticosteroid use in women over 50, dosage in last year, duration of oral corticosteroid use, prescription for fracture prevention (drug used), and referrals for bone densitometry. Methods: General practice records from 41 practices in Shropshire identified 62 230 women aged >50 from a population of 80 082. Data on fractures, duration of corticosteroid use, dose in the study year (1 April 1997–31 March 1998), use of fracture prevention therapy and bone densitometry were sampled from one out of three records. Results: 3.2% were prescribed corticosteroids; 633 patients investigated in detail aged 70.1 (SD 10.5) years, had been prescribed 1526 (SD 1727) mg prednisolone (median 1040 mg) for 3.31 (SD 3.20) years (median 2.0 years). Patients with asthma/lung disease, most common in the younger group, had the lowest annual corticosteroid use; patients with rheumatoid arthritis (RA), polymyalgia rheumatica/temporal arteritis (PMR/TA), who were more likely to be elderly, had the highest annual use. Between the age of 70 and 79 years patients with RA had significantly more hip fractures than the other groups, and corticosteroid prescribing was most common. Bisphosphonates or hormone replacement therapy were prescribed for 48% aged 50–59 years but only 32% at 70–79 years (p
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.62.4.350